Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

 

GPs can safely reduce the number of antihypertensive medications taken by some older people without substantial changes to blood pressure control, finds new research from the Universities of Oxford, Cambridge and Southampton.The OPTIMise results infographic

A potential major consequence of lockdown measures introduced to tackle the COVID-19 pandemic is that fewer patients are seeing their doctor for check-ups and management of their chronic conditions.

One area likely to be neglected is polypharmacy – taking multiple medications for multiple conditions – which is common in older people and can be complicated to manage. Polypharmacy cannot be ignored, as it may increase the risk of side effects to medications due to harmful drug interactions. As such, particularly in older patients prescribed multiple medications, it is generally desirable to regularly review whether these all need to be continued.

This NIHR funded study, published today in The Journal of the American Medical Association, showed that in some older people it is possible for GPs to reduce the number of blood pressure lowering medications people take with limited impact on their blood pressure control or quality of life. The trial showed over a period of 12 weeks, blood pressure remained well controlled (150 mm Hg or less) in 86.4% of patients in the medication reduction arm and 87.7% of patients in the usual care arm, with two thirds of those in the medication reduction group taking fewer medications at the end of the study.

Dr Jenni Burt, Senior Social Scientist at the University of Cambridge’s Primary Care Unit said: “During this pandemic, it is vital that chronic conditions such as hypertension continue to be managed and medicines reviewed for their appropriateness. More than half of patients aged 80 or older will have high blood pressure, and many of them may be taking two or more different drugs to control it. Since blood pressure medications are prescribed for prevention rather than to alleviate symptoms, they are an ideal target for reducing polypharmacy, particularly when the benefits of continued treatment might not outweigh the harms.”

Dr James Sheppard, University Research Lecturer at Oxford University’s Nuffield Department of Primary Care Health Sciences, and co-chief investigator on the study, said: “Blood pressure medications are proven to reduce a person’s risk of stroke and heart attack, but for some, they may also cause fainting and falls or kidney problems, so called ‘adverse events’. This trial shows that when someone is concerned about the risk of adverse events, it is possible to reduce the number of tablets being taken and still achieve good blood pressure control, which is important for preventing stroke.”

The ‘non-inferiority’ trial – designed to demonstrate that medication reduction is no worse than usual care (continuing all medication) – was conducted in 69 GP surgeries across the Midlands and South of England. Over 550 participants aged 80 years or older with well-controlled blood pressure taking two or more antihypertensives were included in the study. Nearly all (98%) were living with at least 2 chronic conditions, bringing the average number of medications up to four per person.

Richard McManus, a practising GP, Professor of Primary Care Research at Oxford University and co-chief investigator on the study, said: “For clinicians concerned that older patients may be taking too many medications, we’ve shown that in the short term it’s possible to safely reduce the number of antihypertensive medications. However, the impacts of medication reduction for longer than 12 weeks weren’t tested in this study, so these results should be treated cautiously, and colleagues should carefully consider individual patient’s circumstances when deciding whether or not to deprescribe blood pressure medication.”

This study was originally funded by the NIHR CLAHRC Oxford and NIHR SPCR.

Similar stories

Three out of four people with heart failure could be diagnosed sooner, potentially improving quality of life and reducing costs to the healthcare system

Researchers from the University of Oxford have today reported that only 1 in 4 people diagnosed with heart failure received a simple, recommended blood test that could have resulted in an earlier diagnosis at a more treatable stage.

Arm and shoulder disability and pain after breast cancer surgery reduced by exercise

The debilitating arm and shoulder disability and pain that some women who have had breast cancer surgery experience as a side effect of their surgery can be reduced by following a physiotherapy-led exercise programme after their operation, a new study has found.

Willingness of Children and Adolescents to have COVID-19 Vaccination

The OxWell School Survey 2021 highlights that younger children and adolescents are the least willing to have the COVID-19 vaccination. These young people come from the most socioeconomically deprived backgrounds, feel less belonging to their school community and think they have probably had COVID-19 already.

Cancer-risk research featured in special edition of PLOS Medicine focussed on advances in early cancer detection

The research is highlighted in a special collection of studies that focus on early cancer detection, hailed by the Editors as “cutting edge, and potentially scalable, innovations that have the potential to inform research, policy, and clinical cancer management.”

The legacy of the CLAHRCs 2014-19 – 5 years of NIHR-funded applied health research

This publication compiles key research projects from the NIHR Collaborations for Leadership in Applied Health Research and Care (CLAHRCs).

NIHR ARC OxTV supported PRINCIPLE trial 'highly commended' for innovative use of health data

The PRINCIPLE trial, which the NIHR ARC OxTV was a fundamental part of setting up in the early days of the pandemic, has been highly commended at the Health Data Research UK Awards for the way in which patient data is utilised so participants are contacted about the trial soon after receiving a positive test result.